Current Management of Early and Advanced Rectal Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (15 November 2022) | Viewed by 37602
Special Issue Editor
Special Issue Information
Dear Colleagues,
In 2020, multimodal management of rectal cancer is still a matter of debate. From the surgical point of view, anterior rectal resection has been the standard of care for a long time. However, in the era of personalized medicine, surgical approaches should also be tailored. Early rectal cancer might be treated by open or minimally invasive local excision, but its feasibility and oncologic safety after neoadjuvant chemoradiation are still controversial. At the same time, locally recurrent or stage IV rectal cancers require a multimodal approach, which is still not completely standardized nor feasible outside tertiary referral centers. Induction chemotherapy, re-chemoradiation, hadrontherapy, totally neoadjuvant treatment, organ-saving strategies, radiomics, indocyanine green-guided surgery, beyond-TME resections, and extending indications for sphincter-saving surgery are not widely performed, but could potentially optimize the treatment strategy. The aim of this Special Issue is to provide an up-to-date milieu of papers focused on the evolving multimodal therapy for rectal cancer.
Dr. Filiberto Belli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- early rectal cancer
- advanced rectal cancer
- locally recurrent rectal cancer
- multimodal treatment
- neoadjuvant chemoradiation
- indocyanine green
- pelvic exenteratio
- sphincter-saving surgery